

References

I-229

1. Abramson HN. B-cell maturation antigen (bcma) as a target for new drug development in relapsed and/or refractory multiple myeloma. *International Journal of Molecular Sciences*. 2020;21(15):5192.
2. Soekojo CY, Ooi M, de Mel S, Chng WJ. Immunotherapy in multiple myeloma. *Cells*. 2020;9(3):601.
3. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomized, open-label, phase 2 study. *The Lancet*. 2020;21:207-221.
4. Blenrep (belantamab mafodotin-blmf) for injection, for intravenous use. GlaxoSmithKline. Research Triangle Park, NC. Revised 02/2022.
5. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Belantamab mafodotin.
6. Micromedex DrugDex Compendium®. 2022. Belantamab mafodotin.
7. National Comprehensive Cancer Network (NCCN). Belantamab mafodotin. NCCN Drugs and Biologics Compendium®. 2022.
8. Lonial S, Lee HC, Badros A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. *Cancer*. 2021;127(22):4198-4212.